← Veeva Systems overview

Veeva Systems vs Doximity: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Veeva Systems Inc Class A (VEEV)

Q3 2026
▲3

Veeva beats Q2, raises guidance, and lands Eli Lilly as global CRM client

  • Eli Lilly commits to Veeva Vault CRM globally Eli Lilly will roll out Veeva's Vault CRM across its global operations. This is a big customer win: it shows top drugmakers will put critical sales software on Veeva's platform, which supports future subscription and services revenue.

    A major new customer commitment directly supports Veeva's growth outlook and is a core reason the stock is moving.

  • Q2 earnings and revenue beat estimates Veeva reported quarterly profit of $2.35 per share and revenue of $928 million, both above analyst expectations. Revenue grew 17.6% from a year earlier. Beating estimates shows the business is performing better than Wall Street expected, which pushes the stock up.

    The earnings beat is the main new financial event driving the stock higher this period.

  • Full-year guidance raised on AI momentum Management raised full-year revenue and profit guidance, citing AI as a new growth chapter. Vault CRM had its best quarter ever, and Veeva Falcon is accelerating. Higher guidance tells investors future results will be stronger than previously thought, lifting the stock.

    Raised guidance changes forward expectations, a key driver of the stock's move.

  • Leadership change and valuation caution Veeva's president and chief customer officer will leave in October, with a new sales and services head named. Also, the stock's price-to-earnings ratio of 45 is well above the industry average, leaving little room for error if growth slows.

    This is the real counterweight: a management change and high valuation could limit gains or add risk.

August 2026
▲3

Veeva beats Q2, raises guidance, and lands Eli Lilly as global CRM client

  • Eli Lilly commits to Veeva Vault CRM globally Eli Lilly will roll out Veeva's Vault CRM across its global operations. This is a big customer win: it shows top drugmakers will put critical sales software on Veeva's platform, which supports future subscription and services revenue.

    A major new customer commitment directly supports Veeva's growth outlook and is a core reason the stock is moving.

  • Q2 earnings and revenue beat estimates Veeva reported quarterly profit of $2.35 per share and revenue of $928 million, both above analyst expectations. Revenue grew 17.6% from a year earlier. Beating estimates shows the business is performing better than Wall Street expected, which pushes the stock up.

    The earnings beat is the main new financial event driving the stock higher this period.

  • Full-year guidance raised on AI momentum Management raised full-year revenue and profit guidance, citing AI as a new growth chapter. Vault CRM had its best quarter ever, and Veeva Falcon is accelerating. Higher guidance tells investors future results will be stronger than previously thought, lifting the stock.

    Raised guidance changes forward expectations, a key driver of the stock's move.

  • Leadership change and valuation caution Veeva's president and chief customer officer will leave in October, with a new sales and services head named. Also, the stock's price-to-earnings ratio of 45 is well above the industry average, leaving little room for error if growth slows.

    This is the real counterweight: a management change and high valuation could limit gains or add risk.

Latest
▲3

Veeva beats Q2, raises guidance, and lands Eli Lilly as global CRM client

  • Eli Lilly commits to Veeva Vault CRM globally Eli Lilly will roll out Veeva's Vault CRM across its global operations. This is a big customer win: it shows top drugmakers will put critical sales software on Veeva's platform, which supports future subscription and services revenue.

    A major new customer commitment directly supports Veeva's growth outlook and is a core reason the stock is moving.

  • Q2 earnings and revenue beat estimates Veeva reported quarterly profit of $2.35 per share and revenue of $928 million, both above analyst expectations. Revenue grew 17.6% from a year earlier. Beating estimates shows the business is performing better than Wall Street expected, which pushes the stock up.

    The earnings beat is the main new financial event driving the stock higher this period.

  • Full-year guidance raised on AI momentum Management raised full-year revenue and profit guidance, citing AI as a new growth chapter. Vault CRM had its best quarter ever, and Veeva Falcon is accelerating. Higher guidance tells investors future results will be stronger than previously thought, lifting the stock.

    Raised guidance changes forward expectations, a key driver of the stock's move.

  • Leadership change and valuation caution Veeva's president and chief customer officer will leave in October, with a new sales and services head named. Also, the stock's price-to-earnings ratio of 45 is well above the industry average, leaving little room for error if growth slows.

    This is the real counterweight: a management change and high valuation could limit gains or add risk.

Q2 2026
▲3▼1

Veeva's AI Push and Earnings Beat Drive Gains, Fed Clouds Outlook

  • AI product launches and acquisition Veeva acquired Copli and launched Veeva Falcon MLR, an AI tool that automates medical, legal, and regulatory reviews, cutting manual work by over 70%. This expands Veeva's AI offerings and could boost future sales, pushing the stock up.

    This is a major new product and acquisition that directly drives VEEV's growth prospects.

  • Strong Q1 earnings and raised guidance Veeva beat earnings and revenue estimates, with subscription revenue up 15% and total revenue up 16%. The company raised full-year revenue guidance, signaling confidence. This positive financial performance supports a higher stock price.

    Earnings beat and guidance raise are key fundamental drivers of the stock's recent rise.

  • Fed signals no rate cuts, pressuring software stocks The Federal Reserve held rates steady and removed expectations for a 2026 cut, even hinting at a possible hike. Higher rates reduce the present value of future profits, which hurts software companies like Veeva. The stock fell 4.7% on the news.

    Monetary policy directly affects VEEV's valuation as a growth stock.

  • Nvidia CEO endorses AI's benefit to software Jensen Huang said AI will improve software companies, not replace them, naming Veeva as a potential winner. This endorsement boosts investor confidence in Veeva's AI strategy and long-term demand.

    High-profile support for AI in software can lift sentiment and demand for VEEV.

June 2026
▲3▼1

Veeva's AI Push and Earnings Beat Drive Gains, Fed Clouds Outlook

  • AI product launches and acquisition Veeva acquired Copli and launched Veeva Falcon MLR, an AI tool that automates medical, legal, and regulatory reviews, cutting manual work by over 70%. This expands Veeva's AI offerings and could boost future sales, pushing the stock up.

    This is a major new product and acquisition that directly drives VEEV's growth prospects.

  • Strong Q1 earnings and raised guidance Veeva beat earnings and revenue estimates, with subscription revenue up 15% and total revenue up 16%. The company raised full-year revenue guidance, signaling confidence. This positive financial performance supports a higher stock price.

    Earnings beat and guidance raise are key fundamental drivers of the stock's recent rise.

  • Fed signals no rate cuts, pressuring software stocks The Federal Reserve held rates steady and removed expectations for a 2026 cut, even hinting at a possible hike. Higher rates reduce the present value of future profits, which hurts software companies like Veeva. The stock fell 4.7% on the news.

    Monetary policy directly affects VEEV's valuation as a growth stock.

  • Nvidia CEO endorses AI's benefit to software Jensen Huang said AI will improve software companies, not replace them, naming Veeva as a potential winner. This endorsement boosts investor confidence in Veeva's AI strategy and long-term demand.

    High-profile support for AI in software can lift sentiment and demand for VEEV.

▲3▼1

Veeva's AI Push and Earnings Beat Drive Gains, Fed Clouds Outlook

  • AI product launches and acquisition Veeva acquired Copli and launched Veeva Falcon MLR, an AI tool that automates medical, legal, and regulatory reviews, cutting manual work by over 70%. This expands Veeva's AI offerings and could boost future sales, pushing the stock up.

    This is a major new product and acquisition that directly drives VEEV's growth prospects.

  • Strong Q1 earnings and raised guidance Veeva beat earnings and revenue estimates, with subscription revenue up 15% and total revenue up 16%. The company raised full-year revenue guidance, signaling confidence. This positive financial performance supports a higher stock price.

    Earnings beat and guidance raise are key fundamental drivers of the stock's recent rise.

  • Fed signals no rate cuts, pressuring software stocks The Federal Reserve held rates steady and removed expectations for a 2026 cut, even hinting at a possible hike. Higher rates reduce the present value of future profits, which hurts software companies like Veeva. The stock fell 4.7% on the news.

    Monetary policy directly affects VEEV's valuation as a growth stock.

  • Nvidia CEO endorses AI's benefit to software Jensen Huang said AI will improve software companies, not replace them, naming Veeva as a potential winner. This endorsement boosts investor confidence in Veeva's AI strategy and long-term demand.

    High-profile support for AI in software can lift sentiment and demand for VEEV.

Doximity Inc (DOCS)

Q3 2026
▲3▼1

Doximity's AI Bet Pays Off With Blowout Quarter, But Margins Shrink

  • Blowout Q1 earnings and raised guidance Doximity reported fiscal Q1 revenue of $156.6 million, beating the $151.7 million consensus, and raised its full-year targets. The stock soared 66% in premarket trading. This directly boosts the share price because it shows the business is growing faster than expected and management is confident enough to raise guidance.

    This is the single biggest new event of the period and the main reason DOCS moved sharply higher.

  • AI investments show strong returns CEO Jeff Tangney said AI prompt volume grew over 25% quarter-on-quarter and AI Scribe users jumped tenfold year-over-year. An independent study found Doximity's AI assistant had the lowest clinical error rates. This supports the stock because it shows the company's heavy AI spending is producing real user growth and a competitive edge.

    It explains why investors are optimistic about the AI strategy despite near-term costs.

  • AI spending squeezes profit margins Adjusted gross margin fell 300 basis points to 88% due to higher AI compute costs, and management expects adjusted EBITDA margin to drop to 47% for the year. This pressures the stock because it means profits are shrinking even as revenue grows, and the company expects the spending to continue.

    It is the main counterweight to the positive AI news and a key reason the stock doesn't just go straight up.

  • AI Search and clinical AI adoption accelerate Doximity's AI Search business onboarded its first cohort across more than two dozen programs, and quarterly active workflow prescribers rose over 30% year-over-year, with 165 signed health-system AI clients. This lifts the stock because it shows new AI products are gaining traction and opening a multibillion-dollar market beyond the core physician network.

    It provides concrete evidence that the AI pivot is translating into new customers and revenue streams.

July 2026
▲3▼1

Doximity's AI Bet Pays Off With Blowout Quarter, But Margins Shrink

  • Blowout Q1 earnings and raised guidance Doximity reported fiscal Q1 revenue of $156.6 million, beating the $151.7 million consensus, and raised its full-year targets. The stock soared 66% in premarket trading. This directly boosts the share price because it shows the business is growing faster than expected and management is confident enough to raise guidance.

    This is the single biggest new event of the period and the main reason DOCS moved sharply higher.

  • AI investments show strong returns CEO Jeff Tangney said AI prompt volume grew over 25% quarter-on-quarter and AI Scribe users jumped tenfold year-over-year. An independent study found Doximity's AI assistant had the lowest clinical error rates. This supports the stock because it shows the company's heavy AI spending is producing real user growth and a competitive edge.

    It explains why investors are optimistic about the AI strategy despite near-term costs.

  • AI spending squeezes profit margins Adjusted gross margin fell 300 basis points to 88% due to higher AI compute costs, and management expects adjusted EBITDA margin to drop to 47% for the year. This pressures the stock because it means profits are shrinking even as revenue grows, and the company expects the spending to continue.

    It is the main counterweight to the positive AI news and a key reason the stock doesn't just go straight up.

  • AI Search and clinical AI adoption accelerate Doximity's AI Search business onboarded its first cohort across more than two dozen programs, and quarterly active workflow prescribers rose over 30% year-over-year, with 165 signed health-system AI clients. This lifts the stock because it shows new AI products are gaining traction and opening a multibillion-dollar market beyond the core physician network.

    It provides concrete evidence that the AI pivot is translating into new customers and revenue streams.

Latest
▲3▼1

Doximity's AI Bet Pays Off With Blowout Quarter, But Margins Shrink

  • Blowout Q1 earnings and raised guidance Doximity reported fiscal Q1 revenue of $156.6 million, beating the $151.7 million consensus, and raised its full-year targets. The stock soared 66% in premarket trading. This directly boosts the share price because it shows the business is growing faster than expected and management is confident enough to raise guidance.

    This is the single biggest new event of the period and the main reason DOCS moved sharply higher.

  • AI investments show strong returns CEO Jeff Tangney said AI prompt volume grew over 25% quarter-on-quarter and AI Scribe users jumped tenfold year-over-year. An independent study found Doximity's AI assistant had the lowest clinical error rates. This supports the stock because it shows the company's heavy AI spending is producing real user growth and a competitive edge.

    It explains why investors are optimistic about the AI strategy despite near-term costs.

  • AI spending squeezes profit margins Adjusted gross margin fell 300 basis points to 88% due to higher AI compute costs, and management expects adjusted EBITDA margin to drop to 47% for the year. This pressures the stock because it means profits are shrinking even as revenue grows, and the company expects the spending to continue.

    It is the main counterweight to the positive AI news and a key reason the stock doesn't just go straight up.

  • AI Search and clinical AI adoption accelerate Doximity's AI Search business onboarded its first cohort across more than two dozen programs, and quarterly active workflow prescribers rose over 30% year-over-year, with 165 signed health-system AI clients. This lifts the stock because it shows new AI products are gaining traction and opening a multibillion-dollar market beyond the core physician network.

    It provides concrete evidence that the AI pivot is translating into new customers and revenue streams.

© 2026 MarketDXWhy